Although KRAS has been shown to play a central role in primary and acquired resistance to anti-EGFR therapy in CRC as well as in other therapeutic contexts, no effective pharmacological inhibitors of KRAS, or other RAS oncoproteins, have reached the clinic to date35. This evidence concerns the gene KRAS and colorectal carcinoma.